Rhodia's Acquisition of ChiRex Underscores Fine Chem Biz.(Brief Article)

Chemical Market Reporter, July, 2000 by CHANG, JOSEPH

Wall Street says Cambrex could be the next target. IN THE LATEST deal highlighting the chemical industry's growing appetite for fine chemicals, France-based Rhodia SA has agreed to acquire ChiRex Inc. for $31.25 per share in cash, or $545 million including the assumption of $35 million in debt.

The deal could have positive implications for Cambrex and Catalytica, the two remaining public pharmaceutical fine chemical manufacturers in the US (related stories, pages 6 and 8). "This acquisition reflects our corporate strategy of building leadership positions in specialty businesses with high value-added activities and strong growth potential," says Rhodia chairman and CEO JeanPierre Tirouflet. "One major area of focus, where we have been gaining...

Premium Content Partnership | HighBeam Research provides an in-depth online archive library of reference works. HighBeam Research
 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)

advertisement
advertisement
  • Click Here
  • Click Here
  • Click Here
advertisement
Click Here